Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis

Experimental Dermatology

Volumn 18, Issue 7, 2009, Pages 643-649

  Demerjian, Marianne ^a   Choi, Eung Ho ^a   Man, Mao Qiang ^a   Chang, Sandra ^a   Elias, Peter M ^a   Feingold, Kenneth R ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Epidermal differentiation; Filaggrin; Involucrin; Keratinocyte proliferation; Loricrin; Permeability barrier; Stratum corneum

Indexed keywords

22 HYDROXYCHOLESTEROL; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CERAMIDE; CHOLESTEROL; CIGLITAZONE; CLOBETASOL; CLOFIBRATE; CYCLINE; FATTY ACID; FILAGGRIN; GLUCOCORTICOID; GW 50156; INVOLUCRIN; LORICRIN; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS; FEMALE; HAIRLESS MOUSE; KERATINOCYTE; MALE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN EXPRESSION; SKIN DISEASE; SKIN PERMEABILITY; SKINFOLD THICKNESS; STRATUM CORNEUM;

ANIMALS; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CLOBETASOL; CLOFIBRATE; DNA-BINDING PROTEINS; EPIDERMIS; FEMALE; GLUCOCORTICOIDS; HYDROXYCHOLESTEROLS; KERATINOCYTES; MALE; MICE; MICE, HAIRLESS; MODELS, ANIMAL; PPAR ALPHA; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES;

EID: 66949166039     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00841.x     Document Type: Article

References (36)

1. Schafer-Korting M, Kleuser B, Ahmed M, Holtje H D, Korting H C. Glucocorticoids for human skin: New aspects of the mechanism of action. Skin Pharmacol Physiol 2005: 18: 103-114.
2. Jackson S, Gilchrist H, Nesbitt L T Jr. Update on the dermatologic use of systemic glucocorticosteroids. Dermatol Ther 2007: 20: 187-205.
3. Hengge U R, Ruzicka T, Schwartz R A, Cork M J. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006: 54: 1-15, quiz 16-18.
4. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006: 15: 406-420.
5. du Vivier A, Phillips H, Hehir M. Applications of glucocorticosteroids. The effects of twice-daily vs once-every-other-day applications on mouse epidermal cell DNA synthesis. Arch Dermatol 1982: 118: 305-308.
6. Laurence E B, Christophers E. Selective action of hydrocortisone on postmitotic epidermal cells in vivo. J Invest Dermatol 1976: 66: 222-229.
7. Sheu H M, Lee J Y, Chai C Y, Kuo K W. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997: 136: 884-890.
8. Sheu H M, Tai C L, Kuo K W, Yu H S, Chai C Y. Modulation of epidermal terminal differentiation in patients after long-term topical corticosteroids. J Dermatol 1991: 18: 454-464.
9. Kao J S, Fluhr J W, Man M Q et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: Inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003: 120: 456-464.
10. Elias P M, Feingold K R. Permeability barrier homeostasis. In: Elias P M, Feingold K R, eds. Skin Barrier. New York: Taylor & Francis, 2006: 337-362.
11. Micallef L, Belaubre F, Pinon A et al. Effects of extracellular calcium on the growth-differentiation switch in immortalized keratinocyte HaCaT cells compared with normal human keratinocytes. Exp Dermatol 2008: 18: 143-151.
12. Kuenzli S, Saurat J H. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol 2003: 149: 229-236.
13. Schmuth M, Jiang Y J, Dubrac S, Elias P M, Feingold K R. Thematic review series: Skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008: 49: 499-509.
14. Sertznig P, Seifert M, Tilgen W, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) and the human skin: Importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 2008: 9: 15-31.
15. Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 2007: 1771: 991-998.
16. Russell L E, Harrison W J, Bahta A W, Zouboulis C C, Burrin J M, Philpott M P. Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp Dermatol 2007: 16: 844-852.
17. Hanley K, Jiang Y, He S S et.al. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J Invest Dermatol 1998: 110: 368-375.
18. Schmuth M, Haqq C M, Cairns W J et al. Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 2004: 122: 971-983.
19. Hanley K, Ng D C, He S S et al. Oxysterols induce differentiation in human keratinocytes and increase Ap-1-dependent involucrin transcription. J Invest Dermatol 2000: 114: 545-553.
20. Komuves L G, Schmuth M, Fowler A J et al. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J Invest Dermatol 2002: 118: 25-34.
21. Mao-Qiang M, Fowler A J, Schmuth M et al. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 2004: 123: 305-312.
22. Jiang Y J, Kim P, Elias P M, Feingold K R. LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes. J Lipid Res 2005: 46: 2657-2666.
23. Strott C A, Higashi Y. Cholesterol sulfate in human physiology: What's it all about? J Lipid Res 2003: 44: 1268-1278.
24. Jiang Y J, Lu B, Kim P et al. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. J Invest Dermatol 2008: 128: 104-109.
25. Man M Q, Choi E H, Schmuth M et al. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: Liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 2006: 126: 386-392.
26. Demerjian M, Man M Q, Choi E H et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 2006: 15: 154-160.
27. Man M M, Feingold K R, Thornfeldt C R, Elias P M. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996: 106: 1096-1101.
28. Mao-Qiang M, Brown B E, Wu-Pong S, Feingold K R, Elias P M. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol 1995: 131: 809-816.
29. Sheu M Y, Fowler A J, Kao J et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 2002: 118: 94-101.
30. Fowler A J, Sheu M Y, Schmuth M et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: Liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 2003: 120: 246-255.
31. Ellis C N, Varani J, Fisher G J et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000: 136: 609-616.
32. Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: An open-label pilot study. Rheumatology (Oxford, England) 2005: 44: 126-129.
33. Kippenberger S, Loitsch S M, Grundmann-Kollmann M et al. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 2001: 117: 1430-1436.
34. Staumont-Salle D, Abboud G, Brenuchon C et al. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 2008: 121: 962-968, e966.
35. Varani J, Bhagavathula N, Ellis C N, Pershadsingh H A. Thiazolidinediones: Potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. Expert Opin Invest Drugs 2006: 15: 1453-1468.
36. Venkatraman M S, Chittiboyina A, Meingassner J et al. Alpha-lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. Arch Dermatol Res 2004: 296: 97-104.